Answers are grounded in this paper and cite their sources.
Polyendocrine metabolic ovarian syndrome (PMOS) is a heterogeneous endocrine–metabolic disorder in which ovarian dysfunction is increasingly linked to metal-ion dyshomeostasis and regulated cell death. Accumulating evidence implicates ferroptosis in PMOS, whereas cuproptosis has recently emerged as a potential contributor. Ferroptosis is driven by iron accumulation, lipid peroxidation, and glutathione (GSH)–glutathione peroxidase 4 (GPX4) axis disruption. Evidence from patient-derived granulosa cells, experimental PMOS models, and pathway-related studies supports a contributory role for ferroptosis in granulosa cell injury, impaired folliculogenesis, and ovulatory dysfunction. Cuproptosis is associated with copper overload, aggregation of lipoylated mitochondrial proteins, and destabilization of Fe–S clusters. Although PMOS-specific data remain limited, several indirect observations suggest a possible association between cuproptosis-related processes and PMOS. Together, these pathways may shape the pathological ovarian microenvironment and contribute to the reproductive and metabolic abnormalities in PMOS. This review integrates current evidence on the molecular mechanisms linking ferroptosis and cuproptosis to PMOS and highlights their potential diagnostic and therapeutic relevance. Further investigations are needed to clarify the molecular mechanisms and interplay between these pathways to facilitate the development of biomarker-guided and targeted strategies for PMOS.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: